甲素抑制剂尼特洛克及其衍生物抑制SARS-CoV-2感染
Rafaela Milan Bonotto1, Ana Mitrović2, Izidor Sosič3
1Laboratory of Molecular Virology, The International Centre for Genetic Engineering and Biotechnology (ICGEB), Padriciano, 99, 34149, Trieste, Italy.
选择性甲素B抑制剂,如氧,通过阻止病毒的进入,有效地破坏SARS-CoV-2 (导致COVID-19的病毒) 感染. 这些发现表明,针对宿主酶的潜在的新型COVID-19治疗方法.
科学领域:
- 病毒学 病毒学
- 药物发现 药物发现 药物发现
- 分子生物学分子生物学
背景情况:
- 在SARS-CoV-2大流行需要新的抗病毒策略,针对关键的病毒或宿主因素.
- 宿主酶,特别是甲素B和L,被确定为SARS-CoV-2进入细胞的关键.
研究的目的:
- 研究选择性甲素抑制剂对SARS-CoV-2的抗病毒潜力.
- 评估尼特洛克索林及其衍生物作为COVID-19治疗药物的疗效.
主要方法:
- 在体外评估甲素抑制剂对SARS-CoV-2感染的影响.
- 对细胞类型的依赖性和与细胞内甲素B/L水平和活性相关性的分析.
- 测试抑制剂对不同SARS-CoV-2变体 (祖先D614和Omicron BA.1_4) 的有效性.
主要成果:
- 选择性甲素B抑制剂,包括尼트로林,在体外证明了SARS-CoV-2感染的显著减弱.
- 在病毒进入的早期阶段观察到抗病毒活性,并且取决于细胞类型和甲素B/L表达/功能.
- 测试的抑制剂对祖先的SARS-CoV-2和Omicron BA.1_4变种都显示出有效性.
结论:
- 主体氨酸甲素B在SARS-CoV-2进入中起着至关重要的作用.
- 素特异性抑制剂,如氧衍生物,代表了治疗COVID-19的有前途的治疗策略.
- 对于抗病毒疗法中的药物重用,尼托克索林需要进一步调查.
更多相关视频
08:41Live Imaging and Quantification of Viral Infection in K18 hACE2 Transgenic Mice Using Reporter-Expressing Recombinant SARS-CoV-2
Published on: November 5, 2021
10:29Quantitative Structure-Activity Relationship, Activity Prediction, and Molecular Dynamics of Non-nucleotide Reverse Transcriptase Inhibitors
Published on: May 9, 2025
相关概念视频
Indirect-Acting Cholinergic Agonists: Chemistry and Structure-Activity Relationship
Reversible inhibitors display short to medium durations of action. Short-acting agents include simple alcohols with...
Indirect-Acting Cholinergic Agonists: Mechanism of Action
Reversible inhibitors like edrophonium bind to a specific part of the enzyme called the anionic catalytic site. They form noncovalent bonds, which means they are not strongly attached to the enzyme. This creates a temporary and less stable enzyme–inhibitor complex, leading to...
Coronavirus
Inhibitors of Viral Protein Synthesis
Inhibitors Of Virion Release
Antiviral Nucleoside Inhibitors
